d9211bb8b8
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Pentagon-Agent: Vida <HEADLESS>
57 lines
5.4 KiB
Markdown
57 lines
5.4 KiB
Markdown
---
|
|
type: source
|
|
title: "New Omada Health Analysis Shows Long-Term Weight Maintenance Post-GLP-1 Discontinuation"
|
|
author: "Omada Health (GlobeNewswire / Omada Insights Lab ANSWERS initiative)"
|
|
url: https://www.globenewswire.com/news-release/2025/09/08/3146152/0/en/New-Omada-Health-Analysis-Shows-Long-Term-Weight-Maintenance-Post-GLP-1-Discontinuation-Challenging-Industry-Assumptions.html
|
|
date: 2025-09-08
|
|
domain: health
|
|
secondary_domains: []
|
|
format: press release
|
|
status: unprocessed
|
|
priority: medium
|
|
tags: [GLP-1, behavioral-wraparound, post-discontinuation, Omada, adherence, digital-health, program-completers]
|
|
---
|
|
|
|
## Content
|
|
|
|
Omada Health released results from the Omada Insights Lab ANSWERS (ANalyzing Success of WEight medication with Real-world evidence and Stats) initiative, examining GLP-1 discontinuation and subsequent weight outcomes for Omada GLP-1 Care Track members.
|
|
|
|
**Key quantitative results:**
|
|
- 63% of Omada members maintained or continued to lose weight 12 months after discontinuing GLP-1s
|
|
- Average weight change at 12 months post-discontinuation: **+0.8%** (essentially flat)
|
|
- Trajectory: 0.03% average weight change at 6 months; 0.6% at 9 months; 0.8% at 12 months
|
|
- Study population: n=816 members in Omada's GLP-1 Care Track, without diabetes
|
|
- Methodology: Claims-based retrospective analysis
|
|
|
|
**Comparison context:** Clinical trials without behavioral wraparound typically show 11-12% weight gain at 1 year post-discontinuation (Omada's stated comparison benchmark).
|
|
|
|
**Program components:** Dedicated care teams, connected devices, AI-enhanced digital experience, behavioral support for side-effect management, injection guidance, medication access and care plan adherence, resistance training encouragement, protein intake guidance.
|
|
|
|
**Also found — Omada ObesityWeek 2025 presentation:** Additional data showing Omada members on GLP-1s lose more fat, preserve muscle mass, and improve mental health vs. typical GLP-1 use without wraparound.
|
|
|
|
**Industry context:** PBMs increasingly pairing GLP-1 authorizations with lifestyle management programs; most PBMs now announcing partnerships with behavioral wraparound vendors (recognizing combination improves outcomes).
|
|
|
|
## Agent Notes
|
|
|
|
**Why this matters:** This is the source that Session 23 flagged as the most significant finding and put the continuous-treatment claim extraction on HOLD. Now contextualized by the Lancet eClinicalMedicine meta-analyses (archived separately), the interpretation is clearer: Omada's 63% is survivorship-biased program-completers, not representative of the general discontinuing population (who show 60-75% weight regain in meta-analyses). The behavioral wraparound effect is real for engaged populations but doesn't generalize to the access-challenged populations most at risk.
|
|
|
|
**What surprised me:** The near-perfect flatness of the weight trajectory (0.03% at 6mo → 0.8% at 12mo) in Omada's data compared to the meta-analysis trajectory is striking. Even accounting for survivorship bias, the gap between +0.8% (Omada completers) and +60-75% of weight lost (general population) is enormous. This suggests that behavioral wraparound selects FOR or creates a population that almost entirely avoids rebound — but we can't separate selection from causal effect.
|
|
|
|
**What I expected but didn't find:** An independent peer-reviewed study of Omada's results. This is a company press release from their own ANSWERS initiative — the self-reporting bias is a significant limitation. Also didn't find data on the dropout rate from the Omada GLP-1 Care Track (which would help assess survivorship bias severity).
|
|
|
|
**KB connections:**
|
|
- Directly relevant to the continuous-treatment claim (held from Session 23)
|
|
- Now clearly scoped by the meta-analyses: Omada's result = best-case for engaged subpopulation; meta-analysis = general population
|
|
- Connects to: behavioral health infrastructure claims, digital therapeutics effectiveness claims
|
|
- The Calibrate data (13.7% weight loss maintained at 12 months with interrupted access) from Session 23 should be archived separately if not already done
|
|
|
|
**Extraction hints:**
|
|
1. **Claim candidate:** "Comprehensive behavioral wraparound programs may enable near-zero weight regain post-GLP-1 discontinuation for engaged program completers (Omada: +0.8% at 12 months, n=816), but this contrasts sharply with the general discontinuing population (meta-analysis: 60-75% weight regain) — the gap represents survivorship and engagement effects, not generalizable population impact"
|
|
2. Note the industry trend: PBMs pairing GLP-1 authorization with behavioral programs — this is a market response to the continuous-delivery problem, but it applies to commercially insured populations not Medicaid
|
|
|
|
**Context:** September 2025 press release from Omada, coinciding with ObesityWeek 2025. Company-funded analysis, not independent peer review. The program's efficacy is real but generalizability is the key question.
|
|
|
|
## Curator Notes (structured handoff for extractor)
|
|
PRIMARY CONNECTION: Continuous-treatment pending claim and the behavioral wraparound question
|
|
WHY ARCHIVED: Best available evidence for the behavioral wraparound exception to the continuous-delivery requirement — provides the contrast case that necessitates scope qualification
|
|
EXTRACTION HINT: Archive for context alongside the Lancet meta-analyses; the CLAIM to extract is the contrast, not the Omada result alone — "best-case behavioral wraparound vs general population trajectory"
|